In November 2021, Walmart-owned Flipkart agreed to pay about ₹750 crore for a 75.1% stake in the company behind the online pharmacy SastaSundar, valuing the e-pharmacy business at roughly ₹1,150 crore. Three years later, SastaSundar’s parent bought its way back out of that marriage: in October 2024 it sold its remaining stake in the combined Flipkart Health venture for ₹97.17 crore, about an eighth of what Flipkart had paid to get in.
That round trip — sell the crown jewel to a giant, then reclaim the brand after the giant loses interest — is the spine of this story. It is also unusual. Most Indian startups that sell a controlling stake to a strategic buyer disappear into the acquirer. SastaSundar’s founders got their name, their intellectual property and their non-compete rights back, and are now trying to rebuild the same online pharmacy they once handed over. What follows is what they sell, how the money actually moves (the part most write-ups get wrong), and why the listed parent’s profit and loss swings so violently from year to year.
Quick facts
| Company | SastaSundar (operating brand of SastaSundar Healthbuddy Ltd; listed parent renamed Health X Platform Limited, NSE: HEALTHX, in February 2026) |
| Founded | SastaSundar Healthbuddy incorporated in West Bengal in 2011; e-pharmacy sastasundar.com launched 14 January 2014 |
| Founders | Banwari Lal Mittal (chairman) and Ravi Kant Sharma (managing director), earlier founders of a Kolkata financial-services business |
| Businesses | SastaSundar B2C app (medicines, diagnostics, wellness); RetailerShakti B2B pharma distribution; Genu Path Labs diagnostics; financial services |
| Latest FY revenue | FY26 consolidated revenue ₹1,319.27 crore, up 18.75% YoY (year ended 31 March 2026, company results) |
| Latest FY profit/loss | FY26 net loss ₹1.45 crore, sharply narrowed from a ₹133.5 crore loss in FY25 |
| Listed | BSE (533259) and NSE; ticker HEALTHX after the February 2026 rename |
| Market value | Market capitalisation about ₹963 crore ($100 million) as of 8 September 2026 |
| Key shareholders | Promoter Banwari Mittal about 33.4%; Topview Enclaves LLP about 24.8%; investor Ashish Kacholia about 1.1% |
What they do
SastaSundar sells medicines and healthcare online, and it distributes them to physical chemists. Two platforms carry the load:
- SastaSundar (B2C): an app and network of “Healthbuddy” stores selling prescription and over-the-counter medicines, diagnostics (via Genu Path Labs) and wellness products to consumers. At the time of the Flipkart deal the platform worked with more than 490 pharmacies (company-stated, November 2021).
- RetailerShakti (B2B): a digital ordering platform that supplies pharmacies and retailers with pharma and wellness stock. This is the volume engine, run through subsidiary SastaSundar Healthbuddy Ltd (SHBL).
- Genu Path Labs: a diagnostics chain held as a 100% subsidiary of SHBL.
- Financial services: a legacy arm the promoters carried over from their earlier business.
The pitch from day one was authenticity of supply — genuine medicines through a technology-tracked chain — in a market where counterfeit and mis-stored drugs are a real consumer risk.
The origin
The founding insight came from the supply chain, not the storefront. Banwari Lal Mittal and Ravi Kant Sharma had already built a Kolkata financial-services business together from around 2000. Mittal, a finance man by training, went looking for a new venture and, as reported in founder profiles, toured Europe and read World Health Organisation material on medicine distribution before concluding that India’s real problem was not a shortage of pharmacies but a broken, opaque distribution system that let counterfeit and poorly stored drugs through.
So the pair built SastaSundar around a distribution backbone rather than a discount-led shopfront. SastaSundar Healthbuddy was incorporated in West Bengal in 2011, and the consumer e-pharmacy sastasundar.com went live on 14 January 2014. The name itself is the promise in Hindi — “sasta” (cheap) and “sundar” (good) — affordable and genuine. Kolkata, not Bengaluru or Delhi, remained the operational base, which is part of why the company stayed lower-profile than the e-pharmacy names that later crowded the market.
The struggle years
SastaSundar never had the near-death cash crises of a pure venture-funded rocket, in part because it was tied to a listed parent and Japanese strategic backers. Its struggles were slower and structural.
- A crowded, cash-burning category. By the late 2010s e-pharmacy in India was a price war led by far better-funded rivals. SastaSundar chose supply-chain depth over blitz-scaling, which kept it smaller and persistently loss-making at the consumer end.
- Losses through the scale-up. The listed parent, SastaSundar Ventures, reported consolidated net losses through this stretch — for example a ₹9.74 crore loss in the March 2020 quarter and a ₹6.04 crore loss in the March 2021 quarter (company results). Revenue was growing — consolidated revenue rose from about ₹385 crore in FY20 to about ₹546 crore in FY21, up 141.6% — but profitability stayed elusive.
- Regulatory overhang. India’s online-pharmacy rules have been repeatedly challenged and revised, leaving the whole category operating under legal uncertainty for years — a permanent tax on planning for every e-pharmacy, SastaSundar included.
The strategic answer to all of this arrived in 2021, and it looked, at first, like a rescue.
The turning point
On 18 November 2021, Flipkart announced it would take a majority stake in Sastasundar Marketplace Limited, the entity that owned and operated sastasundar.com, to launch its own healthcare arm. Flipkart Health Pvt Ltd went on to acquire 75.1% of the marketplace business; the deal valued that business at roughly ₹1,150 crore, and the founders have said Flipkart paid about ₹750 crore for the 75% stake. SastaSundar Ventures retained the remaining 25%. The acquired business was rebranded Flipkart Health+.
For a Kolkata company that had spent seven years grinding, this was validation and an exit rolled into one: Walmart’s Indian arm, with its pan-India logistics, was buying the e-pharmacy at a valuation the public market had never awarded it.
Then it unwound. Flipkart’s healthcare ambitions cooled, and the numbers on the other side of the round trip are stark:
- October 2024: SastaSundar Healthbuddy sold its entire remaining interest in the combined venture to Flipkart Health Private Limited (Singapore) for ₹97.17 crore — a fraction of the ₹750 crore Flipkart had paid to enter three years earlier.
- January 2025: the partnership formally ended; SastaSundar reclaimed its brand, intellectual property and non-compete rights, and set about relaunching its own SastaSundar app.
- The accounting bruise: the exit put a roughly ₹191 crore loss on the liquidation of the Flipkart Health investment through the FY25 books (per results analysis of the year), which is the single biggest reason the parent swung to a heavy loss that year.
The turning point, in other words, turned twice — and the company that came out the other side is the one now trading as Health X Platform.
The money behind it
SastaSundar’s capital story is unusual: strategic Japanese money and a listed parent, rather than a marquee venture-capital cap table.
- Total raised: about $48.2 million across roughly six rounds from a broad investor base, per Tracxn’s tally.
- Mitsubishi Corporation: committed ₹100 crore (about $12 million) in SastaSundar Healthbuddy in August 2019 (Business Standard / YourStory / Inc42).
- Rohto Pharmaceutical (Japan): invested about $9.82 million (₹70.49 crore) into SastaSundar Healthbuddy, alongside the listed parent (Inc42).
- Valuation before the Flipkart deal: reported at about $125 million in 2019 by TechCrunch; other coverage put it nearer $110 million (about ₹800 crore). Treat it as a range: roughly $110–125 million, pre-Flipkart.
- Flipkart, 2021: about ₹750 crore for 75.1% of the marketplace business, at a roughly ₹1,150 crore enterprise valuation — by far the largest cheque in the story, and the one later partly reversed.
Because the operating company sits under a BSE- and NSE-listed parent, the public market is the other, continuous source of capital and price discovery — which is why so much of the verifiable financial record here comes from exchange filings rather than private-round leaks.
How it makes money
This is the part most summaries get wrong, because they treat “SastaSundar” as a consumer e-pharmacy when the money is overwhelmingly business-to-business.
- B2B distribution is the engine. RetailerShakti supplies pharmacies with medicines and wellness stock. It is high-volume and thin-margin — the classic pharma-distribution economics, where a few percentage points of gross margin ride on very large turnover.
- B2C is the brand, not the bulk. The consumer SastaSundar app earns on the retail spread between what it buys medicines for and what it sells them at, plus diagnostics and wellness. It carries the recognisable name but a small share of revenue.
- Diagnostics and financial services add smaller, separate revenue lines — Genu Path Labs on the health side, and the legacy financial-services arm on the other.
- Where the margin sits: the group has run at a negative operating margin recently — roughly -5.0% in FY25 — because the B2B mix is inherently low-margin and the B2C rebuild costs money up front. The company has said it plans to invest about ₹115 crore over three years (from its October 2024 investor presentation) in technology and brand to push the consumer side toward profitability.
The numbers
Consolidated figures for the listed parent (year ending 31 March; ₹ crore). Note the FY25 loss is dominated by the one-off write-down on the Flipkart exit, not by the operating business:
| Fiscal year | Revenue (₹ crore) | Net profit/(loss) (₹ crore) |
| FY24 (Mar 2024) | ~1,375 | +92 (profit) |
| FY25 (Mar 2025) | ~1,111 | (133.5) |
| FY26 (Mar 2026) | 1,319.27 | (1.45) |
- FY26 revenue: ₹1,319.27 crore, up 18.75% YoY; revenue from operations about ₹1,305.9 crore, up around 20% (company results).
- FY26 loss almost erased: net loss of just ₹1.45 crore, versus ₹133.5 crore in FY25 — a reduction of over 99%. EBITDA was still negative at about -₹65.5 crore.
- 9M FY26 turnaround: nine-month revenue of ₹945.49 crore with a net profit of ₹11.51 crore, against a ₹188.23 crore loss in the prior-year nine months (the prior period carried the Flipkart-exit hit).
- Longer arc: consolidated revenue climbed from about ₹385 crore (FY20) to ₹546 crore (FY21, +141.6%) and on past ₹1,300 crore by FY26 — growth driven by B2B distribution, not the consumer app.
Where the money comes from
The FY26 order-flow split by platform (from the company’s own deck) is the surprise, and it reframes the whole business:
- RetailerShakti (B2B): ₹1,125.4 crore — about 85% of platform revenue.
- SastaSundar (B2C app): ₹155.5 crore — the famous brand, roughly 12%.
- Financial services: ₹94.4 crore.
- Diagnostics (Genu Path Labs): ₹2.2 crore.
The surprise: the name everyone knows — the consumer online pharmacy — is a minority of revenue. Health X Platform is, in cash terms, mostly a low-margin B2B pharma distributor with a consumer brand attached. That is precisely the asset Flipkart wanted (the consumer platform) and precisely the asset that came back cheap; the distribution engine largely stayed with the parent throughout.
The risks
- Going-concern flag at Genu Path Labs. The diagnostics step-down subsidiary has been flagged for material uncertainty over going concern, tied to eroded net worth and current liabilities exceeding current assets (results review). A subsidiary that cannot fund itself becomes a drain on the parent or a write-down waiting to happen — the same pattern that just played out with the Flipkart investment.
- Revenue concentration in a thin-margin business. With roughly 85% of platform revenue from B2B distribution at a group operating margin around -5.0% (FY25), scale does not automatically buy profit. If B2B margins compress, there is little cushion, and the higher-margin consumer rebuild is still early.
- Rebuilding a brand it gave away. Having ceded the consumer platform to Flipkart for three years, SastaSundar must now re-win users and re-earn trust in a category that did not stand still — while spending the planned ₹115 crore to do it. The regulatory uncertainty over online-pharmacy rules in India sits on top of that as a structural risk it does not control.
The takeaway
The transferable lesson is about what you sell when you sell a stake. SastaSundar handed a strategic buyer the shiny consumer platform and kept the unglamorous distribution engine — and when the buyer walked, it was the distribution engine that kept the lights on and the revenue growing past ₹1,300 crore, while the consumer asset came home for a small fraction of its sale price. Owning the boring, cash-generating core, and treating the marquee brand as the optional upside rather than the whole company, is what let SastaSundar survive a failed marriage to one of India’s biggest retailers and still have a business to relaunch. Founders negotiating an acquisition should ask which half of the company they would actually miss if the deal fell apart — and make sure that is the half they keep.
Frequently asked questions
Did Flipkart buy SastaSundar?
Yes, partly. In 2021 Flipkart Health Pvt Ltd acquired 75.1% of Sastasundar Marketplace Limited, the entity running sastasundar.com, for about ₹750 crore, and rebranded it Flipkart Health+. SastaSundar’s listed parent kept about 25%.
Does Flipkart still own SastaSundar?
No. By October 2024 SastaSundar Healthbuddy had sold its remaining interest in the combined venture to Flipkart for ₹97.17 crore, and the partnership formally ended in January 2025. SastaSundar reclaimed its brand, IP and non-compete rights and relaunched its own app.
Who founded SastaSundar?
Banwari Lal Mittal (chairman) and Ravi Kant Sharma (managing director), who had earlier built a Kolkata financial-services business together. SastaSundar Healthbuddy was incorporated in 2011 and the e-pharmacy launched on 14 January 2014.
Is SastaSundar a listed company?
The operating brand sits under a parent listed on the BSE and NSE. That parent, formerly Sastasundar Ventures Limited, was renamed Health X Platform Limited (ticker HEALTHX) in February 2026, with a market capitalisation of about ₹963 crore as of 8 September 2026.
How does SastaSundar make money?
Mostly through B2B pharma distribution via RetailerShakti (about ₹1,125 crore, or roughly 85% of FY26 platform revenue), with the consumer SastaSundar app (₹155.5 crore), financial services and diagnostics making up the rest.
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- TechCrunch — Flipkart to acquire online pharmacy SastaSundar (November 2021)
- Business Standard — Flipkart buys majority stake in SastaSundar (November 2021); Flipkart has ended its partnership with us: SastaSundar (January 2025)
- Bar & Bench — legal advisers on Flipkart’s acquisition of Sastasundar Marketplace (2021/2022)
- EquityBulls — Flipkart Health completes acquisition of 75.1% stake in Sastasundar Marketplace Limited
- Inc42 — SastaSundar’s partnership with Flipkart over (January 2025); Mitsubishi commits ₹100 crore in SastaSundar Healthbuddy (2019); funding profile
- YourStory — Mitsubishi invests ₹100 crore in SastaSundar (August 2019)
- The Weekend Leader — founder profile of Banwari Lal Mittal (founding and 14 January 2014 launch)
- ZaubaCorp — SastaSundar Healthbuddy Limited (incorporation, West Bengal, 2011; CIN U15411WB2011PLC160195)
- Whalesbook — Health X Platform FY26 revenue and net loss; consolidated profit turnaround coverage (2025–2026)
- Multibagg — Health X Platform FY26 results and segment split (2026)
- MarketsMojo — SastaSundar Ventures Q3 FY26 and FY24/FY25 results analysis
- Kotak Securities / Value Research / Simply Wall St / Trendlyne — market capitalisation, ticker rename to HEALTHX, and shareholding (September 2026)
- Tracxn — SastaSundar total funding and investor count
- Trading Economics — USD/INR reference rate (18 September 2026)
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.